Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean‐Charles Soria, Tony Mok, Yi‐Long Wu et al.|The Lancet Oncology|2015Cited by 412
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trialYung‐Jue Bang, Narikazu Boku, Lin Shen et al.|The Lancet Oncology|2017Cited by 291
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung‐Ju Ahn, Maen Hussein, Igor Bondarenko et al.|Journal of Thoracic Oncology|2023Cited by 11